fig1

Figure 1. Epigenetics in PCa. Diagram illustrating how epigenetic changes related to prostate cancer and which inhibitors are in current studies. ASF1A: Anti-silencing function 1A hisotne chaperone; CAF-1: chromatin assembly factor 1; SAFB1: scaffold attachment factor B; DNMT: DNA methyltransferase; EZH2: enhancer of zeste 2 polycomb repressive complex 2 subunit; CBP: CREB-binding protein; BRD4: bromodomain containing 4; BET: bromodomain and extra terminal domain; HDAC: histone deacetylases; KDM1A: lysine demethylase 1A; CM-272: 6-methoxy-2-(5-methylfuran-2-yl)-N-(1-methylpiperidin-4-yl)-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-amine; UNC-06358: 2-cyclohexyl-6-methoxy-N-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine; JQ1: (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; TCP: tranylcypromine; ORY-1001: idademstat; IMG-7289: bomedemstat HCL; INCB059872: 1-((4-(methoxymethyl)-4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)cyclobutane-1-carboxylic acid compound with 4-methylbenzenesulfonic acid (1:2); CC-90011: besylate; ORY-2001: vafidemstat.